Popular Trials
Monoclonal Antibodies
Pembrolizumab + SO-C101 for Advanced/Metastatic Solid Tumors
This trial is testing a new drug, SO-C101, for safety and effectiveness in treating solid tumors. The trial will test the drug alone and in combination with another drug, pembrolizumab.
CAR T-cell Therapy
TIL Therapy for Advanced Cancer
This trial tests a treatment for advanced cancers that haven't responded to standard treatments. It involves reducing the patient's immune cells, then using their own enhanced immune cells to fight the cancer, supported by a drug that boosts immune activity.
Checkpoint Inhibitor
Immunotherapy + Tacrolimus for Cancer in Kidney Transplant Recipients
This trialstudies a combo of drugs to treat kidney transplant recipients' cancer that can't be surgically removed or has spread. Immunotherapy & tacrolimus may help attack the cancer & stop tumor growth. It may work better than surgery, chemo, radiation or targeted therapies.
PD-1/PD-L1 Checkpoint Inhibitor
Combination Immunotherapy for Cancer
This trial tests a combination of treatments that aim to boost the immune system in patients whose cancer has progressed after previous treatments. Some patients may receive an additional therapy if their disease continues to progress.
Popular Filters
Trials for Neuroendocrine Carcinoma Patients
Radiation Therapy
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
This trial will test if it is just as effective to give a higher dose of radiation in 10 treatments as it is to give a lower dose of radiation in 25 treatments for Merkel cell carcinoma patients receiving immunotherapy.
Topoisomerase I inhibitor
FF-10850 Topotecan Liposome Injection for Solid Tumors
This trial tests a new form of a cancer drug called topotecan, which is packed in tiny fat bubbles to make it work better and be safer. It targets patients with advanced ovarian cancer and Merkel cell carcinoma who need new treatment options. The drug stops cancer cells from growing by attacking their DNA.
Trials for NEC Patients
Radiation Therapy
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
This trial will test if it is just as effective to give a higher dose of radiation in 10 treatments as it is to give a lower dose of radiation in 25 treatments for Merkel cell carcinoma patients receiving immunotherapy.
Topoisomerase I inhibitor
FF-10850 Topotecan Liposome Injection for Solid Tumors
This trial tests a new form of a cancer drug called topotecan, which is packed in tiny fat bubbles to make it work better and be safer. It targets patients with advanced ovarian cancer and Merkel cell carcinoma who need new treatment options. The drug stops cancer cells from growing by attacking their DNA.
Trials for Metastatic Patients
Topoisomerase I inhibitor
FF-10850 Topotecan Liposome Injection for Solid Tumors
This trial tests a new form of a cancer drug called topotecan, which is packed in tiny fat bubbles to make it work better and be safer. It targets patients with advanced ovarian cancer and Merkel cell carcinoma who need new treatment options. The drug stops cancer cells from growing by attacking their DNA.
Small Molecule Inhibitor
Navtemadlin +/− Immunotherapy for Skin Cancer
This trial is testing a new drug to treat Merkel cell carcinoma, a type of skin cancer. The drug works by targeting a protein called MDM2. Previous treatments haven't worked for patients with this cancer, so this trial is testing to see if this new drug is effective.
Checkpoint Inhibitor
Immunotherapy + Radiation for Cancer
This trial is studying two different ways to give pembrolizumab (with or without stereotactic body radiation therapy) to see how well it works in treating patients with Merkel cell cancer that has spread to other places in the body.
Trials With No Placebo
Radiation Therapy
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
This trial will test if it is just as effective to give a higher dose of radiation in 10 treatments as it is to give a lower dose of radiation in 25 treatments for Merkel cell carcinoma patients receiving immunotherapy.
Topoisomerase I inhibitor
FF-10850 Topotecan Liposome Injection for Solid Tumors
This trial tests a new form of a cancer drug called topotecan, which is packed in tiny fat bubbles to make it work better and be safer. It targets patients with advanced ovarian cancer and Merkel cell carcinoma who need new treatment options. The drug stops cancer cells from growing by attacking their DNA.
View More Related Trials
Frequently Asked Questions
Introduction to merkel cell carcinoma
What are the top hospitals conducting merkel cell carcinoma research?
When it comes to clinical trials for the rare and aggressive skin cancer known as Merkel cell carcinoma, several top hospitals are leading the way. In Seattle, the University of Washington - Seattle Cancer Care Alliance is making significant strides with two ongoing trials focused on this challenging condition. Since recording their first trial in 2014, they have conducted a total of four studies dedicated to understanding and treating Merkel cell carcinoma. Similarly, Memorial Sloan Kettering Cancer Center in New york has also embraced this important research area with two active clinical trials and an impressive track record of ten completed studies since 2014.
Down in Tampa, Moffitt Cancer Center is another standout institution when it comes to advancing our knowledge of Merkel cell carcinoma. With two ongoing clinical trials and a decade-long history dating back to their initial investigation in 2014, Moffitt continues to contribute valuable insights into this complex disease. Meanwhile, Penn Medicine in Philadelphia may have fewer ongoing trials for Merkel cell carcinoma but still plays an essential role by conducting one active study at present while marking their entry into research on this specific type only last year in 2023.
Last but not least is M D Anderson Cancer Center located in Houston. Although they currently have one active trial focused on Merkel cell carcinoma, their impact shouldn't be underestimated as they've already completed six previous investigations since delving into research for this disease backin 2010.
These medical institutions are united by their commitment to unraveling the mysteries surrounding Merkel cell carcinoma through rigorous scientific inquiry. By pushing boundaries and exploring new treatment avenues through clinical trials, these hospitals bring hope to patients diagnosed with this rare form of cancer across different locations throughout the United States
Which are the best cities for merkel cell carcinoma clinical trials?
When it comes to merkel cell carcinoma clinical trials, several cities are at the forefront of research and development. New york, New York offers 7 active trials that investigate treatments such as KRT-232, Pembrolizumab (MK-3475), and Comprehensive Ablative Radiation Therapy. Anchorage, Alaska also has 7 ongoing trials focusing on Pembrolizumab and other potential interventions. Chicago, Illinois follows closely behind with 6 active studies exploring Pembrolizumab, KRT-232, Retifanlimab, among others. Des Moines in Iowa is another city with 6 active trials investigating treatments like Pembrolizumab. Lastly, Louisville in Kentucky contributes to the research landscape with 4 ongoing trials exploring various treatment options including Pembrolizumab and Retifanlimab. These cities provide individuals diagnosed with merkel cell carcinoma access to cutting-edge clinical trials that strive for advancements in care and improve patient outcomes.
Which are the top treatments for merkel cell carcinoma being explored in clinical trials?
Merkel cell carcinoma, a rare but aggressive form of skin cancer, is the focus of ongoing clinical trials exploring various treatment options. Among the top contenders are:
- Pembrolizumab: Currently being tested in three active trials and with a total of 14 all-time merkel cell carcinoma trials since its debut in 2014.
- Radiation therapy: A promising approach under investigation in one active trial and having one all-time merkel cell carcinoma trial recorded as well, first listed in 2021.
- Comprehensive Ablative Radiation Therapy: Another radiation-based treatment option currently involved in one active trial and featured in one previous merkel cell carcinoma study since 2021.
- Domatinostat with avelumab combination: Under evaluation through one active trial and two all-time merkel cell carcinoma trials dating back to 2020.
- KRT-232: An innovative experimental drug that has entered the scene more recently with promising results; currently undergoing testing in one active trial alongside its sole all-time merit for treating this type of cancer noted from listings beginning in 2019.
These treatments hold immense potential for improving outcomes for patients battling Merkel Cell Carcinoma.
What are the most recent clinical trials for merkel cell carcinoma?
Recent clinical trials in the field of Merkel cell carcinoma have brought forth promising advancements in treatment options. Among these studies is a Phase 2 trial exploring the effectiveness of pembrolizumab, offering hope for improved outcomes for patients with this aggressive form of skin cancer. Additionally, radiation therapy has shown potential as a viable treatment option in Phase 2 trials. Another study involves cemiplimab-rwlc, which exhibited promise during its Phase 1 trial. These recent developments hold significant potential to enhance the management and prognosis of individuals living with Merkel cell carcinoma.
What merkel cell carcinoma clinical trials were recently completed?
Recent advancements in clinical trials for Merkel cell carcinoma hold promise for improved treatments against this aggressive form of skin cancer. Immunomic Therapeutics, Inc., completed a trial for ITI-3000 in June 2022, showcasing the potential of this therapy. In addition to that, Fate Therapeutics concluded their FT500 trial in February 2019, revealing significant insights into its efficacy. It is worth noting that while these two trials demonstrate recent progress, a previous study sponsored by Ludwig Institute for Cancer Research examined Tremelimumab and was completed back in December 2016. These developments underscore the ongoing pursuit of innovative therapies to combat Merkel Cell Carcinoma and improve patient outcomes.